Study S001068

A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01769378
Acronym: AWARD-8
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 300
Start: 2013-01
Primary completion: 2014-12
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Placebo; DRUG:Dulaglutide; DRUG:Glimepiride
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDG

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks [Baseline, 24 Weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008191	Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Ferdinand KC, Cardiovascular diabetology	2023	Systematic review	PMID 36894938 DOI	cites ClinicalTrials.gov:NCT01769378; registry reference DERIVED:36894938